The methods, compositions, and kits of the disclosure provide a novel approach for a whole genome, unbiased DNA analysis method that can be performed on limited amounts of DNA. can be used to analyze DNA to determine its modification status. Aspects of the disclosure relate to a method for amplifying bisulfite-treated deoxyribonucleic acid (DNA) molecules comprising: (a) ligating an adaptor to the DNA molecules, wherein the adaptor comprises a RNA polymerase promoter comprising bisulfite-protected cytosines; (b) treating the ligated DNA molecules with bisulfite; (c) hybridizing the bisulfite-treated DNA molecules with a primer; (d) extending the hybridized primer to make double stranded DNA; and (e) in vitro transcribing the double-stranded DNA to make RNA.

The methods, compositions, and kits of the disclosure provide a novel approach for a whole genome, unbiased DNA analysis method that can be performed on limited amounts of DNA. can be used to analyze DNA to determine its modification status. Aspects of the disclosure relate to a method for amplifying bisulfite-treated deoxyribonucleic acid (DNA) molecules comprising: (a) ligating an adaptor to the DNA molecules, wherein the adaptor comprises a RNA polymerase promoter comprising bisulfite-protected cytosines; (b) treating the ligated DNA molecules with bisulfite; (c) hybridizing the bisulfite-treated DNA molecules with a primer; (d) extending the hybridized primer to make double stranded DNA; and (e) in vitro transcribing the double-stranded DNA to make RNA.

Disclosed herein are biosensors, which may be made from cell lysates, purified enzymes, or a combination thereof, for testing for the presence of a pathogen, such as SARS-CoV-2. The biosensor may be used in the context of a paper-based test, such as a colorimetric COVID-19 test. Methods of using the biosensor are also disclosed.

Disclosed herein are biosensors, which may be made from cell lysates, purified enzymes, or a combination thereof, for testing for the presence of a pathogen, such as SARS-CoV-2. The biosensor may be used in the context of a paper-based test, such as a colorimetric COVID-19 test. Methods of using the biosensor are also disclosed.

An encrypted rolling code, a plurality of differing data bit order patterns, and a plurality of differing data inversion patterns are provided. One then selects a particular one of each of these patterns and uses those selected patterns as transmission characteristics when transmitting at least part of the encrypted rolling code.

An encrypted rolling code, a plurality of differing data bit order patterns, and a plurality of differing data inversion patterns are provided. One then selects a particular one of each of these patterns and uses those selected patterns as transmission characteristics when transmitting at least part of the encrypted rolling code.

The present invention relates to a bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing. Further, the use of a bioreactor for RNA in vitro transcription as described herein is part of the present invention. The present invention relates to an RNA in vitro transcription reactor designed to be operable in an automated manner under GMP-compliant conditions. In particular, said RNA in vitro transcription reactor allows repetitive use of DNA template for various RNA in vitro transcription reactions. Further, the invention relates to an apparatus for RNA manufacturing comprising (a) a module for template DNA synthesis, (b) a module for transcribing DNA into RNA comprising said RNA in vitro transcription reactor, and, optionally, (c) a module for RNA formulation.

The present invention relates to a bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing. Further, the use of a bioreactor for RNA in vitro transcription as described herein is part of the present invention. The present invention relates to an RNA in vitro transcription reactor designed to be operable in an automated manner under GMP-compliant conditions. In particular, said RNA in vitro transcription reactor allows repetitive use of DNA template for various RNA in vitro transcription reactions. Further, the invention relates to an apparatus for RNA manufacturing comprising (a) a module for template DNA synthesis, (b) a module for transcribing DNA into RNA comprising said RNA in vitro transcription reactor, and, optionally, (c) a module for RNA formulation.

Herein provided is a novel method, nanoPARE (parallel analysis of RNA ends from low-input RNA), for generating multiple sequencing libraries from a single full-length cDNA library, specifically an RNA 5′ end sequencing library and/or a gene body cDNA library, and method for analyzing RNA 5′ ends, and optionally associated software developed therefor. Further provided is a cDNA library generated therefor.

Herein provided is a novel method, nanoPARE (parallel analysis of RNA ends from low-input RNA), for generating multiple sequencing libraries from a single full-length cDNA library, specifically an RNA 5′ end sequencing library and/or a gene body cDNA library, and method for analyzing RNA 5′ ends, and optionally associated software developed therefor. Further provided is a cDNA library generated therefor.